by Truveta News | Sep 4, 2024 | News
The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute at the University of Washington’s School of Pharmacy has partnered with Truveta to use its electronic health record (EHR) data to drive comparative, cost-effectiveness, and outcomes research....
by Truveta staff | Jul 30, 2024 | Technology
In this blog I will discuss our approach to scaling our AI technologies across multiple dimensions while controlling development costs, operational costs, and assuring stability. LLMs are a powerful new technology, but they also have large development, operational,...
by Truveta Research | Jul 8, 2024 | Research
Truveta Research’s comparative effectiveness study exploring weight loss among patients taking semaglutide (Ozempic) and tirzepatide (Mounjaro) has been published in JAMA Internal Medicine. Glucagon-like peptide 1 receptor agonist-based (GLP-1 RA) medications,...
by Truveta staff | Jul 2, 2024 | Research
Citation Wang X, Xu Y, Norman G, et al. CGM Use in People with Type 2 Diabetes Initiating GLP-1 or GIP/GLP-1RA Therapy—Real-World Data. Diabetes. June 14, 2024. https://doi.org/10.2337/db24-1922-LB Recently, researchers published new insights in Diabetes exploring the...
by Truveta staff | Jul 1, 2024 | Technology
In this post, I would like to discuss the way we addressed the following challenge: How to ensure that the AI technologies used in our platform have requisite accuracy and explainability while assuring fairness and avoidance of bias Healthcare and life science...
